To effectively fight cancer, we need to understand how it works—the mechanisms that enable it to resist treatment and evade detection from the immune system by turning genes off or on. We are continually making progress in deciphering these mechanisms. I am proud to present this 2023 report highlighting some of our significant research findings and developments during the past year.
For example, we have established novel molecular classifiers that serve as a powerful platform for disease stratification and testing of combination therapeutic strategies. We have developed innovative technology that provides a universal strategy for targeting most undruggable transcription factors. And we have uncovered a clearer understanding of the mechanisms involved in the evolution of pancreatic tumors, which could have tremendous implications for the future design of therapeutics. Our 2023 report covers these and other exciting advances.
The report also features new members of our team whose research expertise and promise will enhance our ability to further decipher the nuances of cancer and develop more effective therapies.
With our commitment to discovery and providing the best, most equitable care to our diverse patient population, and with our outstanding team of dedicated scientists and clinicians, we are on a firm path toward a successful future.
Ramon Parsons, MD, PhD
Director of The Tisch Cancer Institute